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Background: The translocator protein (18 kDa) (TSPO) is a mitochondrial protein expressed on reactive glial cells
and a biomarker for gliosis in the brain. TSPO ligands have been shown to reduce neuroinflammation in several
mouse models of neurodegeneration. Here, we analyzed TSPO expression in mouse and human retinal microglia
and studied the effects of the TSPO ligand XBD173 on microglial functions.
Methods: TSPO protein analyses were performed in retinoschisin-deficient mouse retinas and human retinas.
Lipopolysaccharide (LPS)-challenged BV-2 microglial cells were treated with XBD173 and TSPO shRNAs in vitro and
pro-inflammatory markers were determined by qRT-PCR. The migration potential of microglia was determined with
wound healing assays and the proliferation was studied with Fluorescence Activated Cell Sorting (FACS) analysis.
Microglial neurotoxicity was estimated by nitrite measurement and quantification of caspase 3/7 levels in 661 W
photoreceptors cultured in the presence of microglia-conditioned medium. The effects of XBD173 on filopodia
formation and phagocytosis were analyzed in BV-2 cells and human induced pluripotent stem (iPS) cell-derived
microglia (iPSdM). The morphology of microglia was quantified in mouse retinal explants treated with XBD173.
Results: TSPO was strongly up-regulated in microglial cells of the dystrophic mouse retina and also co-localized
with microglia in human retinas. Constitutive TSPO expression was high in the early postnatal Day 3 mouse retina
and declined to low levels in the adult tissue. TSPO mRNA and protein were also strongly induced in LPS-challenged
BV-2 microglia while the TSPO ligand XBD173 efficiently suppressed transcription of the pro-inflammatory marker genes
chemokine (C-C motif) ligand 2 (CCL2), interleukin 6 (IL6) and inducible nitric oxide (NO)-synthase (iNOS). Moreover,
treatment with XBD173 significantly reduced the migratory capacity and proliferation of microglia, their level of NO
secretion and their neurotoxic activity on 661 W photoreceptor cells. Furthermore, XBD173 treatment of murine and
human microglial cells promoted the formation of filopodia and increased their phagocytic capacity to ingest latex beads
or photoreceptor debris. Finally, treatment with XBD173 reversed the amoeboid alerted phenotype of microglial cells in
explanted organotypic mouse retinal cultures after challenge with LPS.
Conclusions: These findings suggest that TSPO is highly expressed in reactive retinal microglia and a promising target to
control microglial reactivity during retinal degeneration.
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The translocator protein (18 kDa) (TSPO), previously
known as the peripheral benzodiazepine receptor, is an
integral part of the outer mitochondrial membrane [1]
where it forms a complex with other mitochondrial pro-
teins, such as the voltage-dependent anion channel
(VDAC) and the adenine nucleotide transporter (ANT)
[2]. TSPO mediates the transport of cholesterol into the
inner mitochondrial membrane, where it serves as a
precursor for steroids and neurosteroids [3]. Hence, the
protein is constitutively expressed in steroidogenic tis-
sues such as the adrenal gland, the gonads and the brain
[4]. In the central nervous system TSPO is present both
in neurons and activated glial cells [5-7]. Endogenous
ligands of TSPO are cholesterol, porphyrins and active
peptide fragments cleaved off from the diazepam binding
inhibitor [8]. Glial up-regulation of TSPO is a major hall-
mark of neurodegenerative diseases [9] and various TSPO
ligands have been developed as molecular markers to detect
gliosis by means of Positron Emission Tomography (PET)
imaging [10].
TSPO ligands are also under investigation as treatment
options for a variety of neurological disorders, including
Alzheimer’s disease [11], multiple sclerosis [12], neuro-
pathic pain [13], peripheral nerve injury [9] and anxiety
disorders [14]. Classical synthetic TSPO ligands, such
as the benzodiazepine derivative 4′-chlorodiazepam
(Ro5-4864) and the isoquinoline carboxamide PK11195,
directly enhance GABAergic neurotransmission [15].
TSPO ligands such as etifoxine and XBD173 (emapunil)
stimulate the synthesis of neurosteroids and may exert
anti-inflammatory and neuroprotective effects [16].
Inherited retinal degenerations are clinically and genetic-
ally heterogeneous diseases characterized by progressive
vision loss [17]. Although the individual mechanisms of
pathogenesis remain to be resolved, microglial activation
is a common hallmark of retinal degeneration [18]. The
retinoschisin-deficient (Rs1h-/Y) mouse is a prototypic
model for inherited retinal dystrophies with strong micro-
glial reactivity [19,20]. Modulation of retinal microglia
with docosahexaenoic acid could dampen microglial
reactivity in Rs1h-/Y mice and thereby reduced retinal
degeneration [21]. TSPO ligands could potentially have a
similar effect and may target the neurodegenerative cas-
cade via their anti-inflammatory and microglia modulating
effects.
In this study, we showed that TSPO expression is
directly connected to retinal microgliosis in a mouse
model of retinal degeneration and in human retinal sec-
tions. Moreover, we demonstrated that the TSPO ligand
XBD173 induces an anti-inflammatory, neuroprotective
and pro-phagocytic phenotype in microglia using cul-
tures of murine and human microglial cell lines as well
as mouse retinal explants.Methods
Animals
MacGreen [22], Rs1h-/Y [19] and wild-type mice were all
on a pure C57BL/ 6 J background. Animals were main-
tained in an air-conditioned environment on a 12-hour
light–dark schedule at 22°C, and had free access to food
and water. The health of the animals was regularly moni-
tored, and all procedures complied with the German Law
on Animal Protection and the Institute for Laboratory
Animal Research Guide for the Care and Use of Laboratory
Animals, 2011.
Human tissue
Retinal samples of donors were obtained from the Eye
Bank of the Center of Ophthalmology, University of
Cologne, Germany. The donor age ranged between 54
and 72 years. Postmortem time ranged between 5 and
36 h. After dissection of the anterior segment, the
remaining tissue included the posterior pole. The re-
search followed the tenets of the Declaration of Helsinki.
Reagents
E. coli 0111:B4 lipopolysaccharide and aminoglutethi-
mide were purchased from Sigma Aldrich (St. Louis,
MO, USA). XBD173 (emapunil) was obtained by custom
synthesis from APAC Pharmaceuticals (Ellicott City,
MD, USA). XBD173 was dissolved in ethanol.
Cell culture and retinal explants
BV-2 microglia-like cells were cultured in RPMI/5% fetal
calf serum (FCS) supplemented with 2 mM L-Glutamine
and 195 nM β-mercaptoethanol. Isolation and culture of
primary retinal microglia has been described previously
[21]. BV-2 cells were stimulated with 50 ng/ml lipopoly-
saccharide (LPS) and various concentrations of XBD173
or ethanol as vehicle control. 661 W photoreceptor-
like cells were a gift from Prof. Muayyad Al-Ubaidi
(Department of Cell Biology, University of Oklahoma
Health Sciences Center, Oklahoma City, OK, USA) and
the culture conditions have been described elsewhere
[23]. Human microglial cell lines (iPSdM) were gener-
ated from induced pluripotent stem (iPS) cell lines ob-
tained by reprogramming from skin fibroblasts as
previously described [24,25]. These cells proliferate without
addition of growth factors and they were passaged 1:3 twice
a week. The microglial phenotype was confirmed by flow
cytometry (CD11b, CD16/32, CD36, CD45, CX3CR1). Ret-
inas from MacGreen mice were rinsed in DMEM/Ham’s
F12 medium supplemented with 1% FCS and placed on
25 mm circular Nucleopore filters (VWR, Darmstadt,
Germany) with the photoreceptor side facing the mem-
brane. After 24 h of in vitro culture with vehicle, 1 μg/ml
LPS, 20 μM XBD173 or 1 μg/ml LPS + 20 μM XBD173,
retinas were fixed and imaged in flat-mounts. Ramified and
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green fluorescent protein (GFP) fluorescence using the
Axioskop2 MOT Plus Apotome microscope (Carl Zeiss,
Jena, Germany) and counted.
Scratch wound-healing assay
A total of 400,000 BV-2 microglial cells were grown in
six-well plates as 80% confluent monolayers and were
wounded with a sterile 100 μl pipette tip. Thereafter, the
cells were stimulated with 50 ng/ml LPS, 50 μM
XBD173, 50 ng/ml LPS + 50 μM XBD173, or ethanol as
solvent control. Migration into the open scar was docu-
mented with microphotographs taken at different time
points after wounding using a Nikon ECLIPSE TE2000
inverted microscope (Nikon, Tokyo, Japan). The number
of migrating cells was quantified by counting all cells
within a 0.4 mm2 region in the center of each scratch.
The number of migrated cells was then normalized to
the average cell density to account for changes in prolif-
eration. A minimum of five individual cultures was used
to calculate the mean migratory capacity of each cell
culture condition.
Proliferation assay
For carboxyfluorescein diacetate succinimidyl ester (CFSE)
proliferation assays, BV-2 microglial cells were labeled with
1 μM CFSE (e-Bioscience, San Diego, CA, USA) and
cultured (1.5 × 105 per well) in a six-well plate. After 24 h
of culture with vehicle, 100 ng/ml LPS, 50 μM XBD173 or
100 ng/ml LPS + 50 μM XBD173, cells were stained with a
fixable viability dye (e-Bioscience), to exclude dead cells
from the analysis. The fluorescence intensity of CFSE-
labeled BV-2 cells was analyzed by flow cytometry (FACS
Canto II). Analysis of cell division was performed using
FlowJo software (Treestar Inc., Ashland, OR, USA).
shRNA knock-down of TSPO in BV-2 cells
For knockdown of endogenous TSPO in BV-2 cells,
shRNA vectors were obtained from the RNAi consor-
tium (TRC). Briefly, BV-2 cells were transfected with
2.5 μg vector DNA using TransIT®-LT1 transfection re-
agent (Mirus Bio LLC, Madison, WI, USA) to express
TSPO-specific or scrambled shRNAs. Twenty-four hours
after transfection cells were stimulated with vehicle,
50 ng/ml LPS, 20 μM XBD173 or 50 ng/ml LPS + 20 μM
XBD173 for 12 hours before cells were harvested for
RNA isolation and mRNA expression analysis.
661 W photoreceptor apoptosis assay
To test microglial neurotoxicity, a culture system of 661 W
photoreceptors with microglia-conditioned medium was
established. 661 W photoreceptor cells were incubated for
48 h either in their own medium or with culture superna-
tants from unstimulated, 50 ng/ml LPS, 50 μM XBD173 or50 ng/ml LPS + 50 μM XBD173 treated microglial cells.
The 661 W cell morphology was assessed by phase contrast
microscopy and apoptotic cell death was determined with
the Caspase-Glo® 3/7 Assay (Promega GmbH, Mannheim,
Germany). Cells were lysed and incubated with a lumino-
genic caspase-3/7 substrate, which contains the tetrapeptide
sequence DEVD. Luminescence was then generated by
addition of recombinant luciferase and was proportional to
the amount of caspase activity present. The luminescent
signal was read on an Infinite F200 pro plate reader (Tecan,
Crailsheim, Germany). A blank reaction was used to meas-
ure background luminescence associated with the cell
culture system and Caspase-Glo® 3/7 Reagent (Promega).
The value for the blank reaction was subtracted from all
experimental values. Negative control reactions were per-
formed to determine the basal caspase activity of 661 W
cells. Relative luciferase units (RLU) reflect the level of
apoptotic cell death in the different 661 W cell cultures.
Nitrite measurement
Nitric oxide concentrations were determined by measur-
ing the amount of nitrite produced by BV-2 microglial
cells into the culture medium using the Griess reagent
system (Promega). A 50 μl cell culture supernatant was
collected and an equal volume of Griess reagent was
added to each well. After incubation for 15 minutes at
room temperature, the absorbance was read at 540 nm
on an Infinite F200 pro plate reader (Tecan). The con-
centration of nitrite for each sample was calculated from
a sodium nitrite standard curve.
Phagocytosis assays
BV-2 microglial cells were pre-treated for 2 h with
compounds before 4 μl latex bead solution (Polystyrene
microparticles, Sigma Aldrich, St. Louis, MO, USA) was
added to the wells. Cells were incubated for 6 h and five
micrographs per well were taken using an AxioVert.A1
inverted microscope (Carl Zeiss). The phagocytic activity
was determined by calculating the number of cells which
phagocytosed 10 or more latex beads compared to all
cells per field. The conditions for human microglial cells
(iPSdM) were the same with the modification that cells
were pre-treated for 24 h, the incubation time with
beads was 24 h and only fully saturated cells were
counted as positive. To study the microglial uptake of
apoptotic photoreceptor cell material, 661 W photo-
receptor cells were starved with serum deprivation,
harvested and fluorescently labeled using CellTracker
CM-DiI (Invitrogen, Carlsbad, CA, USA). For phagocyt-
osis, BV-2 microglial cells were pre-treated for 2 h with
compounds before 400 μl stained apoptotic 661 W solu-
tion was added for further 6 h. iPSdM cells were pre-
treated for 24 h before 400 μl stained apoptotic 661 W
solution was added for further 24 h. Cells were then
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phenylindole. Fluorescence micrographs were taken and
ImageJ software (National Institutes of Health, Bethesda,
MD, USA) was used to determine the ratio of phagocy-
tosed apoptotic photoreceptor fragments (red signal)
relative to the total microglia cell number (DAPI signal).
Phalloidin staining
BV-2 microglial cells or human microglial cells (iPSdM)
were grown on cover slips in six-well plates and the
indicated compounds were added for 24 h. Thereafter,
the cells were fixed, permeabilized with 0.1% Triton
X-100 and f-actin was fluorescently labeled using 0.1 μg/
ml Phalloidin-TRITC (Sigma). The nuclei were stained
using 4′,6-diamidino-2-phenylindole and photomicro-
graphs were taken with an Axioskop2 MOT Plus Apotome
microscope (Carl Zeiss).
Immunohistochemistry
Immunohistochemical analyses were performed on
10 μm retinal sections embedded in optimal cutting
temperature (OCT) compound (Hartenstein, Würzburg,
Germany) or on retinal flat mounts. Samples were fixed
in 4% paraformaldehyde, rinsed and rehydrated with
PBS. Sections were blocked with a dried milk solution
followed by an overnight incubation with primary
antibodies at 4°C. Antibodies included rabbit anti-Iba1
antibody (Wako Chemicals, Neuss, Germany), rabbit
anti-TSPO antibody (Abcam, Cambridge, UK), goat
anti-MAP2 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and goat anti-GFAP antibody (Santa
Cruz Biotechnology). After washing, samples were la-
beled with a secondary antibody conjugated to Alexa488
(green) or Alexa594 (red) (Jackson Immuno-Research,
West Grove, PA, USA) and counter-stained with DAPI.
Sections and flat-mounts were mounted in DAKO fluor-
escent mounting medium (Dako Deutschland GmbH,
Hamburg, Germany) and viewed with an Axioskop2
MOT Plus Apotome microscope (Carl Zeiss).
Western blot analysis
Mouse retinal tissue was homogenized in cold RIPA buf-
fer (20 mM Na-phosphate buffer, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100 and protease inhibitors) using a
TissueLyser LT (Qiagen, Hilden, Germany). Insoluble
debris was removed by centrifugation for 15 minutes at
16,000 g. LPS-treated and control BV-2 microglia were
directly lysed in RIPA buffer. Protein concentrations
were determined by Bradford assay (Roti-quant, Roth,
Karlsruhe, Germany). A total of 10 μg of microglial or
30 μg of total-retina proteins were separated by SDS-
PAGE on 15% gels with PageRuler pre-stained protein
ladder (Thermo Scientific, Waltham, MA, USA). Pro-
teins were then transferred to 0.45 μm nitrocellulosemembranes (Biorad, Munich, Germany). After blocking
in TBS-T containing 5% nonfat dry milk, membranes
were incubated with primary antibodies against TSPO
(ab109497, Abcam,) or Actin (sc-1616, Santa Cruz
Biotechnology). Blots were then incubated with sec-
ondary goat anti-rabbit IgG-HRP or rabbit anti-goat
IgG-HRP antibodies (sc-2004, sc-2768, Santa Cruz
Biotechnology). Enhanced chemiluminescence signals
were then visualized and imaged with the MultiImage
II system (Alpha Innotech, Santa Clara, CA, USA).
RNA isolation and reverse transcription
Total RNA was extracted from total retina, BV-2 micro-
glial cells or isolated retinal microglia according to the
manufacturer’s instructions using the RNeasy Mini Kit
(Qiagen). Purity and integrity of the RNA was assessed
on the Agilent 2100 Bioanalyzer with the RNA 6000
Nano LabChip® reagent set (Agilent Technologies, Santa
Clara, CA, USA). The RNA was quantified spectro-
photometrically and then stored at −80°C. First-strand
cDNA synthesis was performed with the RevertAid™ H
Minus First Strand cDNA Synthesis Kit (Fermentas,
Schwerte, Germany).
Quantitative real-time RT-PCR
Amplifications of 50 ng cDNA were performed with
an ABI7900HT machine (Applied Biosystems, Carlsbad,
CA, USA) in 10 μl reaction mixtures containing 1 ×
TaqMan Universal PCR Master Mix (Applied Biosys-
tems), 200 nM of primers and 0.25 μl of dual-labeled
probe (Roche ProbeLibrary, Roche Applied Science,
Basel, Switzerland). The reaction parameters were as fol-
lows: 2 minutes 50°C hold, 30 minutes 60°C hold and 5
minutes 95°C hold, followed by 45 cycles of 20 s 94°C
melt and 1 minute 60°C anneal/extension. Primer se-
quences and Roche Library Probe numbers were as fol-
lows: CCL2, forward primer 5′-catccacgtgttggctca-3′,
reverse primer 5′-gatcatcttgctggtgaatgagt-3′, probe #62;
IL6, forward primer 5′-gatggatgctaccaaactggat-3′, re-
verse primer 5′-ccaggtagctatggtactccaga-3′, probe #6;
iNOS, forward primer 5′-ctttgccacggacgagac-3′, reverse
primer 5′- tcattgtactctgagggctga-3′, probe #13. Measure-
ments were performed in triplicates and results were an-
alyzed with an ABI sequence detector software version
2.3 using the ΔΔCt method for relative quantification.
Pregnenolone ELISA
BV-2 cells were seeded on 24-well plates in 1 ml/well of
RPMI/5% FCS supplemented with 2 mM L-Glutamine
and 195 nM β-mercaptoethanol. After cells had attached
after 6 h, 50 ng/ml LPS and/or 20 μM XBD173 were
added to each well. After 21 h, cells were washed twice
with HEPES assay buffer (140 mM NaCl, 5 mM KCl,
1.8 mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 mM
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Then 1 ml of HEPES assay buffer supplemented with
BSA (0.1%) and Trilostane (25 μM) (Sigma-Aldrich)
was added to each well. Again 50 ng/ml LPS and/or
20 μM XBD173 were added. After 3 h the supernatants
were removed to perform pregnenolone ELISA accord-
ing to the manufacturer’s recommendations (IBL
International, Hamburg, Germany). In brief, 50 μl
of each sample were pipetted into a rabbit anti-
pregnenolone antibody coated 96-microwell Plate. A
total of 100 μl of pregnenolone-HRP conjugate was
then added. Ready-to-use-calibrators were provided by
IBL international. After 1 h of incubation and washing
150 μl of tetramethylbenzidine/hydrogen peroxide
(TMB) substrate was added. Assays were read with a
Tecan Spectra at 450 nm. Data were analyzed by
Magellan Data Analysis Software (Tecan).Statistical analyses
Real-time quantitative RT-PCR data were analyzed
with the ΔΔCt method using an unpaired Student’s
t-test. Assays for nitrite secretion, microglial migration
and pregnenolone ELISAs were analyzed with an
unpaired Student’s t test. Caspase 3/7 assays and
phagocytosis assays were analyzed with a Mann–
Whitney U-test. P <0.05 was considered as statistically
significant.Figure 1 TSPO expression as a marker for microgliosis in degeneratin
photomicrographs show low TSPO expression in retinal microglia (green G
expression in astrocytes (red TSPO immunofluorescence) (A-C) but strong
The overlap of TSPO and Iba1 immunostaining also indicates co-expression
not co-localize with the Müller cell marker GFAP (J, K) or the neuronal mic
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, gan
protein (18 kDa); GFAP, glial fibrillary acid protein; MAP2, microtubule-assocResults
Induction of TSPO expression in activated microglia of
the retina
To identify genes regulated during activation of microglia,
we have previously performed DNA microarray analysis
of isolated retinal microglial cells from degenerating
retinoschisin-deficient (Rs1h-/Y) and control macrophage/
microglia MacGreen reporter mice [21]. Among the differ-
ently expressed transcripts, a significantly increased mRNA
expression of TSPO was detected in activated retinal
microglia (data not shown). Therefore, we determined the
protein expression of TSPO in the retina and found a weak
expression in the MacGreen reporter mouse, which was
present in ramified microglia of the plexiform layers and
astrocytes of the ganglion cell layer (Figure 1A-C). How-
ever, there was a remarkable increase of TSPO expression
specifically in microglia of MacGreen/Rs1h-/Y retinas
(Figure 1D-F). Notably, there was nearly a full overlap of
TSPO signals with amoeboid microglial cells which mi-
grated to the degenerating inner nuclear layer (Figure 1F).
In the human retina, TSPO expression was also evident in
inner plexiform layer microglial cells as demonstrated
by Iba1 co-immunostaining as well as in astrocytes
(Figure 1G-I). To exclude that TSPO is significantly
expressed in Müller cells or retinal neurons, immunos-
tainings for glial fibrillary acid protein (GFAP) and
microtubule-associated protein 2 (MAP2) were per-
formed. Neither wild-type retinas nor Rs1h-/Y retinasg and aging retinas. In MacGreen mice, representative
FP signal and red TSPO immunofluorescence) and constitutive
up-regulation in retinal microglia from MacGreen/Rs1h-/Y mice (D-F).
in human retinal microglia (G-I). TSPO immunostaining staining does
rotubule marker MAP2 (L, M). ONL, outer nuclear layer; OPL, outer
glion cell layer, GFP, green fluorescent protein; TSPO, translocator
iated protein 2. Scale bar, 50 μm.
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(Figure 1J, K) or MAP2 (Figure 1L, M), respectively.
To further verify the steep TSPO expression in react-
ive microglia, mRNA analysis of isolated retinal micro-
glia from MacGreen and MacGreen/Rs1h-/Y retinas was
performed. There was a strong and significant increase of
TSPO mRNA in MacGreen/Rs1h-/Y microglia (12.01 ±
0.82, P <0.01) compared to MacGreen microglia (1.0 ±
1.07) (Figure 2A). TSPO induction was also confirmed on
the protein level when total retinas of MacGreen/Rs1h-/Y
mice compared to MacGreen mice were analyzed
(Figure 2B). We next performed TSPO transcript ana-
lysis in early postnatal development of the mouse
retina. TSPO was present at higher levels in early
retinal development and turned to lower levels in the
adult retina (Figure 2C). We then analyzed whether the
induction of TSPO expression is also present in cul-
tured BV-2 microglia, which were activated by LPS.
Treatment of BV-2 cells with 50 ng/ml LPS elicited a
highly significant increase in TSPO levels (4.11 ± 0.31,
P <0.001) compared to vehicle-treated BV-2 cells
(1.0 ± 0.80) (Figure 2D). The increase of TSPO in LPS-
activated BV-2 microglia was also confirmed on the
protein level using Western blot analysis (Figure 2E).
The selective TSPO ligand XBD173 dampens pro-
inflammatory and neurotoxic microglial activation
We investigated whether stimulation of TSPO with the se-
lective ligand XBD173 influences microglial reactivity. We
first tested the mRNA expression of the chemo-attractant
protein CCL2, the pro-inflammatory cytokine IL6 and
iNOS in LPS-activated microglia upon treatment with threeFigure 2 TSPO mRNA and protein expression in reactive microglia. (A
from MacGreen/Rs1h-/Y mice compared to MacGreen mice. (B) TSPO prote
MacGreen mice. (C) Temporal TSPO mRNA expression profiling shows a hig
levels in adult mouse retinas. (D, E) LPS activation of BV-2 microglial cells le
show mean ± SD (n = 3/group, measured in triplicates) **P <0.01 MacGreen
2. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).different doses of XBD173. The TSPO ligand significantly
and dose-dependently suppressed mRNA levels of CCL2
(Figure 3A, P = 0.0014 for 20 μM XBD173 and P = 0.0003
for 50 μM XBD173 versus vehicle control), IL6 (Figure 3B,
P = 0.0004 for 20 μM XBD173 and P = 0.0001 for 50 μM
XBD173 versus vehicle control), and iNOS (Figure 3C,
P = 0.0104 for 20 μM XBD173 and P = 0.0004 for 50 μM
XBD173 versus vehicle control).
To test whether the anti-inflammatory effect of
XBD173 depends on TSPO expression, shRNA mediated
knock-down of TSPO was performed. Transfection of
BV-2 cells with two different TSPO-specific shRNAs
showed a 50 to 60% knock-down of TSPO mRNA levels
compared to a scramble control (data not shown). The
mRNA expression levels of CCL2 (Figure 3D), IL6
(Figure 3E) and iNOS (Figure 3F) were no longer
suppressed by XBD173 treatment when either shRNA1
or shRNA2 that specifically target TSPO were present.
This clearly implicates that the suppressing effect of
XBD173 acts via TSPO in BV-2 cells.
When co-administered together with 50 ng/ml LPS,
50 μM XBD173 also strongly diminished NO-production
from BV-2 microglial cells compared to vehicle-treated cells
(Figure 3G, P <0.0001). We then performed an apoptosis
assay of 661 W photoreceptor cells incubated in the
presence of microglia-conditioned medium. LPS-activated
microglial cells incubated in the presence of 50 μM
XBD173 had a significantly lower pro-apoptotic effect on
photoreceptor cells than microglia cultured with vehicle
(Figure 3H, P <0.0022).
We then analyzed the effect of the TSPO ligand on
microglial migration. Stimulation of BV-2 microglial cells) Strong induction of TSPO mRNA levels in isolated microglial cells
in induction in total retinas from MacGreen/Rs1h-/Y mice compared to
h early postnatal expression level and continuous decline to low
ads to the induction of TSPO transcripts (D) and protein (E). Data
/Rs1h-/Y versus MacGreen; ***P <0.001 BV-2 + 50 ng/ml LPS versus BV-
Figure 3 The TSPO agonist XBD173 dampens gene transcription of pro-inflammatory markers and reduces microglial neurotoxicity.
LPS-activated BV-2 microglial cells were cultured in the presence of various concentrations of XBD173 for 24 h and the pro-inflammatory
transcript markers CCL2 (A), IL6 (B), iNOS (C) were determined by real time qRT-PCR. Data show mean ± SD (n = 3/group, measured in triplicates)
*P <0.05, **P <0.01, ***P <0.001 XBD173 + LPS versus LPS-treated cells. (D-F), Knock-down of TSPO with two independent shRNAs abrogates the
suppressing effects of XBD173 on CCL2 (D), IL6 (E) and iNOS (F) gene expression in BV-2 cells. (G), Production of NO as determined by detection
of nitrite from BV-2 microglial cells treated with 50 μM XBD173 in the absence or presence of 50 ng/ml LPS. Data show mean ± SD (n = 9/group)
***P <0.001 XBD173 + LPS versus LPS-treated cells. (H), 661 W photoreceptor cell cultures were treated with conditioned media from BV-2
microglial cells for 48 hours. The supernatant from control-stimulated, 20 μM XBD173-treated, 50 ng/ml LPS-treated, or 20 μM XBD173 + 50 ng/ml
LPS-treated cells was added to 661 W photoreceptor cells and apoptosis-related caspase 3/7 activation was determined. Data show mean ± SD
(n = 6/group) **P <0.01 XBD173 + LPS versus LPS-treated cells. CCL2, (C-C motif) ligand 2; IL6, interleukin-6; iNOS, inducible nitric oxide synthase;
LPS, lipopolysaccharide; NO, nitric oxide.
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2 cells in a wound-healing scratch assay (Figure 4A). This
effect was quantified and significant in non-activated
microglia (Figure 4B, P <0.0008) as well as LPS-
preactivated BV-2 cells (Figure 4B, P <0.0406). WeFigure 4 The TSPO agonist XBD173 reduces microglial migration and
BV-2 microglia treated with vehicle, 50 ng/ml LPS, 50 μM XBD173 or both.
treatment (B). Data show mean ± SEM (n = 5/group) *P <0.05 XBD173 versu
based proliferation assay of BV-2 microglial cells treated with vehicle, 100 n
liferation rate of BV-2 microglia was analyzed 24 hours after treatment usin
shown. CFSE, carboxyfluorescein diacetate succinimidyl ester; LPS, lipopolysconstantly noticed a reduced cell number in our culture
assays and, therefore, tested a potential anti-mitotic effect
of XBD173. CFSE labeling and FACS analyses clearly dem-
onstrated that XBD173 reduced the proliferation rate of
both unstimulated and LPS-treated BV-2 cells (Figure 4C).proliferation. (A) Scratch assay to mimic wound-healing in cultured
Microphotographs from scratched areas were quantified 8 h after
s control, *P <0.001 XBD173 + LPS versus LPS-treated cells. (C), CFSE-
g/ml LPS, 50 μM XBD173 or 100 ng/ml LPS + 50 μM XBD173. The pro-
g flow cytometry and a representative graph out of four repetitions is
accharide; TSPO, translocator protein (18 kDa).
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in murine and human microglia
To investigate further functional consequences of treat-
ment with the TSPO ligand, we tested the effects of
TSPO activation on the morphology and phagocytosis of
murine BV-2 microglia and human microglial cells
(iPSdM) derived from human induced pluripotent stem
cells. Staining of the f-actin cytoskeleton with phalloidin
indicated that XBD173 caused a prominent formation of
filopodia in murine BV-2 cells either in the absence or
presence of LPS (Figure 5A-D). This effect was even
more pronounced in human iPSdM, which showed a
large rim of flattened filopodia (Figure 5E-H).
This striking phenomenon of XBD173-induced filo-
podia formation prompted us to analyze the phagocytic
capacity in detail using latex beads and CM-DiI-stained
apoptotic 661 W photoreceptor material as a more
physiological trigger. BV-2 microglial cells stimulated
with XBD173 showed a significantly higher phagocytosis
rate of latex beads in non-activated cells (Figure 6A, B,
P = 0.0013) as well as LPS-preactivated cells (Figure 6A,
B, P = 0.0029). A similar effect of XBD173 was noticed
with fluorescent apoptotic 661 W photoreceptors in
non-activated (Figure 6C, D, P = 0.0192) and LPS-
incubated BV-2 cells (Figure 6C, D, P = 0.0013). XBD173
had a similar stimulating effect on the phagocytic poten-
tial of human microglial cells with strongly increased
uptake of latex beads (Figure 6E, F, P <0.0001) and CM-
DiI-stained apoptotic 661 W membranes (Figure 6G, H,
P <0.0001).
To test whether the phenomenon of XBD173-induced
phagocytosis is dependent on neurosteroid synthesis, we
first quantified pregnenolone levels in BV-2 cells. Stimu-
lation of BV-2 microglia with either 20 μM XBD173
alone (Figure 7A, P <0.0005) or together with 50 ng/ml
LPS (Figure 7A, P <0.0074) strongly increased pregneno-
lone levels measured in the cell culture supernatant. We
next performed bead phagocytosis assays with BV-2 cellsFigure 5 The TSPO ligand XBD173 promotes microglial filopodia form
microglial cells treated with 50 μM XBD173 in the absence or presence of
iPS-derived microglia (iPSdM) treated with 30 μM XBD173 in the absence
translocator protein (18 kDa).stimulated with 20 μM XBD173 in the presence or ab-
sence of the CYP11A1 inhibitor aminoglutethimide. As
previously shown in Figure 6, BV-2 cells stimulated with
XBD173 showed a higher phagocytosis potential than
control cells (Figure 7B, P <0.0001). Interestingly, this
effect was completely prevented when the cells were co-
incubated with 20 μM XBD173 and 100 μM aminoglu-
tethimide (Figure 7B). These data suggest that the
phagocytosis promoting effect of XBD173 requires preg-
nenolone synthesis.XBD173 reduces the number of LPS-alerted amoeboid
microglia in living retinal explants
Finally, we analyzed whether the XBD173-dependent
morphological transformation of microglial cells can
also be observed in the ex vivo retina. Retinas from
MacGreen reporter mice were used to enable easy GFP-
based analysis of microglial ramification. Retinal explants
cultured for 24 h in vitro retained their ramified morph-
ology (Figure 8A) and the microglial network was not
significantly affected by XBD173 alone (Figure 8B). In
contrast, retinal microglia dramatically changed their
morphology in the presence of LPS with a large fraction
of bloated amoeboid cells (Figure 8C). This LPS-induced
morphological transition of microglia was effectively
suppressed by XBD173 (Figure 8D). We then performed
a quantitative analysis of ramified and amoeboid micro-
glial cells in all retinal explants. As already indicated in
Figure 7A-D, the number of amoeboid cells was signifi-
cantly increased in LPS-treated cultures compared
to vehicle-treated explants (Figure 8E, P = 0.0012).
Interestingly, co-incubation of explants with LPS and
XBD173 resulted in a strongly reduced number of
alerted amoeboid microglia cells (Figure 8E, P <0.0001).
Thus, XBD173 was not only able to influence microglial
reactivity in vitro but also significantly affected microglia in
living mouse retinas.ation. (A-D) Representative images of phalloidin-stained murine BV-2
50 ng/ml LPS. (E-H) Representative images of phalloidin-stained human
or presence of 250 ng/ml LPS. LPS, lipopolysaccharide; TSPO,
Figure 6 The TSPO ligand XBD173 increases microglial phagocytosis. Phagocytosis was monitored in BV-2 cells incubated with latex beads
(A, B) or CM-DiI-stained apoptotic 661 W photoreceptor material (C, D). Data show mean ± SEM (n = 9/group) **P <0.01 XBD173 + LPS versus
LPS-treated cells, *P <0.05 XBD173 versus vehicle-treated cells. Phagocytosis was monitored in human iPSdM cells incubated with latex beads
(E, F) or CM-DiI-stained apoptotic 661 W photoreceptor material (G, H). Data show mean ± SEM (n = 9/group) ***P <0.01 XBD173 + LPS versus
LPS-treated cell and XBD173 versus vehicle-treated cells. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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Based on its selective expression in activated glial cells
of the brain, TSPO is a marker for brain gliosis and
TSPO ligands have been developed for in vivo imaging
in human and mouse [27,28]. In the present study, we
now show that selective up-regulation of TSPO is closely
associated with the reactivity of microglia during retinal
degeneration. To our knowledge, this is the first report
to identify TSPO as a biomarker of activated microglia
both in mouse and human retinal tissue. Major ques-
tions are why and how TSPO is up-regulated in reactive
retinal microglia. Microgliosis in the retina of a mouse
model of retinoschisin-deficiency starts at postnatal Day
14, peaks at P21 and then declines to lower levels [29].
The peak of microglial reactivity perfectly overlaps with
high induction of TSPO expression levels. In the brain,Figure 7 The TSPO ligand XBD173 increases pregnenolone levels and
Pregnenolone levels in cell culture supernatants of BV-2 cells treated with 2
hours. Data show mean ± SD (n = 3/group) ***P <0.001 XBD173 versus veh
Quantification of latex bead phagocytosis of BV-2 cells treated with 20 μM
Data show mean ± SEM (n = 30/group) ***P <0.0001 XBD173 versus controTSPO detects activation of both microglia and astrocytes
as a result of injury but also during recovery from injury
[30,31], indicating that the presence of TSPO on acti-
vated glia may be a self-limiting mechanism of activation
and proliferation. Our data of up-regulated TSPO ex-
pression in LPS-stimulated BV-2 microglia revealed that
TLR4 signaling may play a crucial role in TSPO induc-
tion. In line with our experiments, up-regulation of
TSPO in the recovery phase from neuropathic pain was
prevented by pharmacological blockade of TLR4 [13].
We, therefore, hypothesize that retinal damage and the
presence of damage-associated molecular patterns may
trigger TLR4 signaling on microglia and thereby influ-
ence TSPO expression.
Our experiments demonstrate that the selective TSPO
ligand XBD173 efficiently reversed the LPS-triggeredCYP11A1 inhibition prevents XBD173-induced phagocytosis. (A)
0 μM XBD173, 50 ng/ml LPS, or 20 μM XBD173 + 50 ng/ml LPS for 24
icle-treated cells, **P <0.01 XBD173 + LPS versus LPS-treated cells. (B)
XBD173 or 20 μM XBD173 + 100 μM aminoglutethimide for 24 hours.
l cells. LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
Figure 8 The TSPO ligand XBD173 reduces the number of alerted amoeboid retinal microglia ex vivo. (A-D) Representative GFP images
of the retinal microglia network in explanted mouse retinas treated for 24 hours with vehicle (A), 20 μM XBD173 (B), 1 μg/ml LPS + vehicle (C)
and 1 μg/ml LPS + 20 μM XBD173 (D). (E) Quantification of ramified and amoeboid microglial cells in 10 independent image areas of two
individual flat mounts (mean ± SEM). **P <0.01 for amoeboid cells in LPS versus control explants; ***P <0.0001, for amoeboid cells in XBD173 +
LPS versus LPS-treated explants. GFP, green fluorescent protein; LPS, lipopolysaccharide; TSPO, translocator protein (18 kDa).
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IL6 and iNOS. The TSPO ligand and mitochondrial
effector PK11195 effectively inhibited LPS-induced
microglial expression of COX-2 and TNF-alpha via
modulation of Ca2+-mediated signaling pathways [32].
The same compound reduced the expression of pro-
inflammatory cytokines and neuronal apoptosis in
quinolinic-acid-treated rat brain [33]. These findings
together with our data on the global influence of
XBD173 on gene expression revealed that targeting
TSPO has a broad influence on inflammatory signaling
in microglia. As we have shown in microglial cell
culture, one potential mechanism of the effects of
XBD173 could be the synthesis of pregnenolone, as
has been previously shown for astrocytes [34]. These
findings support the concept that microglia locally
synthesize the anti-inflammatory neurosteroid precursor
pregnenolone after activation of TSPO by respective
ligands.
Our studies revealed that TSPO significantly influenced
the f-actin cytoskeleton and fostered the formation of
filopodia along with prominent effects on microglial migra-
tion and phagocytosis. A high phagocytic activity with a
low migratory capacity is a typical hallmark of homeostatic
microglia which constantly survey their environment with
long protrusions [35]. Over the last years it has also become
clear that microglial phagocytosis of apoptotic cells is
largely anti-inflammatory [36]. Thus, we hypothesize that
induction of TSPO signaling may shift alerted microglia to
a more homeostatic and less inflammatory state. In line
with this, TSPO ligands have been shown to influence
chemotaxis and phagocytosis in peripheral blood cells
[37-39]. TSPO overexpression also increased the prolifera-
tion and migratory capacity of rat C6 glioma cells whereas
treatment with the TSPO ligand PK11195 had a strong
anti-proliferative effect and exerted pro-apoptotic activityon these cells [40]. Treatment of LPS-challenged microglia
with XBD173 could effectively reduce the number of
amoeboid cells in the explanted mouse retina but did not
significantly increase the fraction of ramified cells. This
clearly indicates that TSPO signaling may serve to control
microglia dynamics during the activation and/or resolution
phase of retinal damage. In the native retina, endogenous
ligands for TSPO may fulfill this function. Several endogen-
ous molecules that bind TSPO have been identified in
steroidogenic tissues, including the protein diazepam
binding inhibitor (DBI) [41]. DBI can be cleaved into sev-
eral active peptide fragments such as octadecaneuropeptide
(ODN) and trikontatetraneuropeptide (TTN) which are
released from astrocytes [10]. TTN then stimulates neuro-
synthesis in C6 glioma cells by acting on TSPO [8]. Thus,
we hypothesize that either retinal astrocytes or Müller cells
may express DBI and secrete active peptides to control
microglial activity via targeting of TSPO.Conclusions
We have shown that TSPO is highly expressed in react-
ive retinal microglia and BV-2 cells stimulated with
LPS. The selective TSPO ligand XBD173 efficiently
dampened pro-inflammatory gene expression in BV-2
microglial cells and reduced their neurotoxic potential
on 661 W photoreceptor cells. XBD173 treatment of
BV-2 cells and human iPS-derived microglial cells also
promoted filopodia formation and phagocytic uptake.
In the explanted mouse retina, XBD173 treatment
blocked the LPS-dependent accumulation of amoeboid
microglial cells. In conclusion, our data implicate that
TSPO expression is connected to retinal microglia re-
activity and that selective TSPO ligands may be a
promising therapeutic approach to dampen microglio-
sis during retinal degeneration.
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